FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Biblioteca de Peptidos

HMG

Human Menopausal Gonadotropin / Menopur / Pergonal

Sexual Health

Human Menopausal Gonadotropin (HMG) is a urinary-derived preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in approximately equal proportions, extracted and purified from the urine of postmenopausal women. It is FDA-approved for the treatment of infertility in both men and women, stimulating follicular development in women and spermatogenesis in men. Brand names include Menopur and Pergonal, and it remains a cornerstone of assisted reproductive technology.

Mecanismo de Acción

Combination of FSH and LH extracted from post-menopausal urine. Directly stimulates ovarian follicular development (FSH component) and supports ovulation and corpus luteum function (LH component). Used in assisted reproduction protocols.

Protocolos de Investigación

Para propósitos de investigación solo. No es asesoramiento médico.

Fertility protocols use 75-150 IU daily via intramuscular injection, adjusted based on ovarian response monitoring. Male protocols for spermatogenesis use 75-150 IU 2-3 times weekly with HCG.

Notas de Investigación

Clinical Research Status

HMG has been used in fertility medicine since the 1960s and holds FDA approval for ovulation induction in women with anovulatory infertility and for spermatogenesis stimulation in men with hypogonadotropic hypogonadism. Highly purified urinary HMG (Menopur) and recombinant alternatives (Gonal-F for FSH, Luveris for LH) provide different formulation options. Ongoing research compares urinary-derived versus recombinant gonadotropins for IVF outcomes.

Key Published Findings

Clinical trials demonstrate that HMG protocols produce equivalent or slightly superior IVF outcomes compared to recombinant FSH alone, possibly due to the LH component's contribution to follicular steroidogenesis. In male infertility, HMG combined with HCG can restore spermatogenesis in men with gonadotropin deficiency, with sperm appearing in ejaculate typically within 6-18 months. The LH activity in HMG supports theca cell androgen production necessary for optimal follicular development.

Safety Profile

Ovarian hyperstimulation syndrome (OHSS) is the most significant risk, ranging from mild (abdominal bloating) to severe (ascites, thromboembolism), requiring careful ultrasound and estradiol monitoring during stimulation cycles. Multiple pregnancy rates are elevated (15-25% in IUI cycles) due to multi-follicular development. In male patients, adverse effects are generally limited to gynecomastia and acne from increased testosterone and estrogen production.

Comparison to Related Compounds

Unlike recombinant FSH (follitropin alfa/beta), HMG contains both FSH and LH activity, providing a more complete gonadotropin stimulus. Compared to HCG which mimics only LH, HMG provides direct FSH stimulation critical for Sertoli cell function and spermatogenesis initiation. Highly purified HMG (Menopur) contains LH activity primarily from HCG co-purified from urine rather than true LH, though biological activity is equivalent.

Community Observations

Fertility specialists often debate the clinical significance of the LH component in HMG versus pure FSH protocols, with some evidence favoring HMG in specific patient populations (older women, poor responders). In male fertility protocols, HMG is typically added to HCG after initial testosterone normalization to specifically target spermatogenesis. Cost considerations remain relevant as urinary-derived preparations are generally less expensive than recombinant alternatives.

Media Vida

~24-48 hours

Reconstitución

Sterile diluent provided with kit

Almacenamiento

Liofilizado

Refrigerate 2-8C.

Reconstituído

Use immediately after reconstitution.

Estado Legal EE.UU.

FDA-approved (Rx only)

También Se Conoce Como

Human Menopausal GonadotropinMenopurPergonal

Preguntas frecuentes

¿Qué es HMG?

Human Menopausal Gonadotropin (HMG) is a urinary-derived preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in approximately equal proportions, extracted and purified from the urine of postmenopausal women. It is FDA-approved for the treatment of infertility in both men and women, stimulating follicular development in women and spermatogenesis in men. Brand names include Menopur and Pergonal, and it remains a cornerstone of assisted reproductive technology.

¿Cómo funciona HMG?

Combination of FSH and LH extracted from post-menopausal urine. Directly stimulates ovarian follicular development (FSH component) and supports ovulation and corpus luteum function (LH component). Used in assisted reproduction protocols.

¿Cuál es el estado regulatorio de HMG en EE. UU.?

FDA-approved (Rx only)

¿Cuál es la vida media de HMG?

~24-48 hours

¿Qué otros nombres tiene HMG?

Human Menopausal Gonadotropin, Menopur, Pergonal

Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.

Leer aviso completo